How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about durvalumab with platinum-based chemotherapy, then with or without olaparib

Marketing authorisation indication

2.1

Durvalumab (Imfinzi, AstraZeneca) in combination with platinum-based chemotherapy is indicated for 'the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with:

  • durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)

  • durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR)'.

2.2

Olaparib (Lynparza, AstraZeneca) in combination with durvalumab is indicated for 'the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel'.

Price

2.4

The list price of durvalumab is £592 for a 120‑mg vial and £2,466 for a 500‑mg vial (excluding VAT; BNF online accessed March 2025).

2.5

The list price of olaparib is £2,317.50 per 56-pack of 100-mg and 150-mg tablets (excluding VAT; BNF online accessed March 2025).

2.6

The company has confidential commercial access agreements with NHS England. This makes durvalumab and olaparib available to the NHS with a discount, and the discount for olaparib would also have applied to this indication if durvalumab with platinum-based chemotherapy, then durvalumab plus olaparib had been recommended. The size of the discounts are commercial in confidence.

Comments panel open